Kasper defined much of what is known about the pathogenesis of GBS infection and developed an understanding of the polysaccharide conformational epitopes required for induction of protective antibodies. Kasper's work led to a highly immunogenic glycoconjugate vaccine, which is now in clinical trials in a novel approach, pregnant women are immunized and then transplacentally transfer antibodies to protect the baby.
His group discovered that antibodies to the bacterial capsule are deficient in babies with GBS disease. His laboratory elucidated the structure of all nine capsular polysaccharides and important surface proteins of this major neonatal pathogen. Kasper discovered and developed vaccines against group B Streptococcus (GBS), the foremost cause of serious neonatal bacterial infections. His studies innovatively integrate microbiology, immunology, structural carbohydrate and lipid chemistry, biochemistry, and genetics.Dr. Dennis Kasper has conducted research in microbiology, immunology, infectious diseases, and public health while discharging a broad range of administrative and educational responsibilities.
0 kommentar(er)
